Clinical and cost avoidance benefits of integrating pharmacist inintensive care unit
Main Article Content
Keywords
intensive care unit, Cost, pharmacist, intervention
Abstract
Introduction: Critical care pharmacists as integral members of multidisciplinary teams, play a crucial role in enhancing clinical, economic and humanistic outcomes for all critically ill patients. In this region, however, the economic impact of critical care pharmacist have not been well investigated.Objectives: The purpose of this study was to classify and estimate critical care pharmacist interventions that are associated with cost avoidance in the intensive care units. Methods:This was a single center prospective, observational study conducted at a 30-bed adult medical and surgical intensive care unit for over 12 months. Interventions performed by the critical care pharmacist and accepted by the multidisciplinary intensive care teams were documented weekly. Interventions were retrieved monthly to be categorized and quantified for cost estimation using two systematic frameworks. Total cost avoidance was calculated by aggregating the cost avoidance values for each intervention. The average rates of cost avoidance per month were computed by dividing the total cost avoidance by the number of months the critical care pharmacist provided care. For the net benefit, we subtracted the cost of the clinical pharmacist service from the total cost savings.Results:For a cohort of 239 critically ill patients, a total of 912 interventions were recommended. Forty percent of critical care pharmacist interventions were related to the optimization of antibiotics. Cost avoidances were mainly observed in adverse event prevention (n = 170; 18%), which resulted in a cost savings of $336,189.2 and individualized patient care accounted for (n = 486; 53%) and resulted in cost savings of $304,905.46 The total cost avoidance was $697,254.1 with a benefit‒cost ratio of 5.7:1.Conclusion:The presence of pharmacists in the intensive care unit has resulted in significant cost avoidance, mainly in adverse event prevention and individualized patient care, with a substantial return on investment.
References
2. Hawkins WA, Butler SA, Poirier N, Wilson CS, Long MK, Smith SE. From theory to bedside: Implementation of fluid stewardshipin a medical ICU pharmacy practice. Am J Health Syst Pharm. 2022;79(12):984-92. https://doi.org/10.1093/ajhp/zxab453
3. Leape LL. Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care Unit. JAMA. 1999;282(3):267. https://doi.org/10.1001/jama.282.3.267
4. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23);2483-7. https://doi.org/10.2146/ajhp060674
5. MacLaren R, Bond CA, Martin SJ, Fike D. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med. 2008;36(12):3184-9. https://doi.org/10.1097/ccm.0b013e31818f2269
6. MacLaren R, Bond CA. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events. Pharmacotherapy. 2009;29(7):761-8. https://doi.org/10.1592/phco.29.7.761
7. Alshaya AI, Alhammad AM, Ismail N, Alkhani N, Alharbi S, Alenazi AO, et al. Critical care pharmacy in Saudi Arabia: Historical evolution and future directions—A review by the Critical Care and Emergency Medicine Pharmacy Specialty Network at the Saudi Society of Clinical Pharmacy. JACCP J Am Coll Clin Pharm. 2021;4(11).
8. Rech MA, Gurnani PK, Peppard WJ, Smetana KS, Van Berkel MA, Hammond DA, et al. Pharmacist avoidance or reductions in medical costs in critically ill adults. Crit Care Explor. 2021;3(12):e0594. https://doi.org/10.1097/cce.0000000000000594
9. Preslaski CR, Lat I, MacLaren R, Poston J. Pharmacist contributions as members of the multidisciplinary ICU team. Chest. 2013;144(5). https://doi.org/10.1378/chest.12-1615
10. Al-Jazairi AS, Al-Agil AA, Asiri YA, Al-Kholi TA, Akhras NS, Horanieh BK. The impact of clinical pharmacist in a cardiac-surgery intensive care unit. Saudi Med J. 2008;29(2):277-81.
11. Aljbouri TM, Alkhawaldeh MS, Abu-Rumman A eddeen K, Hasan TA, Khattar HM, Abu-Oliem AS. Impact of clinical pharmacist on cost of drug therapy in the ICU. Saudi Pharm J. 2013;21(4):371-4. https://doi.org/10.1016/j.jsps.2012.12.004
12. Houso A, Hamdan M, Falana H. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study. Saudi Pharm J. 2022;30(12):1718-24. https://doi.org/10.1016/j.jsps.2022.09.017
13. Hammond DA, Gurnani PK, Flannery AH, Smetana KS, Westrick JC, Lat I, et al. Scoping Review of Interventions Associated with Cost Avoidance Able to Be Performed in the Intensive Care Unit and Emergency Department. Pharmacotherapy.2019;39(3):215-31. https://doi.org/10.1002/phar.2224
14. U.S. B of LS. U.S. Bureau of Labor Statistics [Internet]. CPI calculator. [cited 2023 Feb 28]. Available from: https://data.bls.gov/cgi-bin/cpicalc.pl
15. Hammond DA, Flowers HJC, Meena N, Painter JT, Rech MA. Cost avoidance associated with clinical pharmacist presence in a medical intensive care unit. JACCP J Am Coll Clin Pharm. 2019;2(6).ax
16. Muñoz-Pichuante D, Villa-Zapata L. Benefit of Incorporating Clinical Pharmacists in an Adult Intensive Care Unit: A Cost-saving Study. J Clin Pharm Ther. 2020;45(5):1127-33. https://doi.org/10.1111/jcpt.13195
17. Wang T, Benedict N, Olsen KM, Luan R, Zhu X, Zhou N, et al. Effect of critical care pharmacist’s intervention on medication errors: A systematic review and meta-analysis of observational studies. J Crit Care. 2015;30(5):1101-6. https://doi.org/10.1016/j.jcrc.2015.06.018
18. Lee H, Ryu K, Sohn Y, Kim J, Suh GY, Kim E. Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis*. Crit Care Med. 2019;47(9):1243-50. https://doi.org/10.1097/ccm.0000000000003830
19. Jiang SP, Zhu ZY, Ma KF, Zheng X, Lu XY. Impact of pharmacist antimicrobial dosing adjustments in septic patients on continuous renal replacement therapy in an intensive care unit. Scand J Infect Dis. 2013;45(12):891-9. https://doi.org/10.3109/00365548.2013.827338
20. Cheung D, Go A, Cooper M, Schwarz K. Evaluation of a pharmacist-driven renal dosing protocol at an academic medical center.JACCP J Am Coll Clin Pharm. 2020;3(4).
21. Aljuhani O. Critical care pharmacy services in the Western Region of Saudi Arabia. Saudi Crit Care J. 2020;4(2):66.
22. Badreldin HA, Alosaimy S, Al‐jedai A. Clinical pharmacy practice in Saudi Arabia: Historical evolution and future perspective.JACCP J Am Coll Clin Pharm. 2020;3(5):920-9.
23. Sikora A, Martin GS. Critical Care Pharmacists: Improving Care by Increasing Access to Medication Expertise. Ann Am Thorac Soc. 2022;19(11):1796-8. https://doi.org/10.1513/annalsats.202206-502vp
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.